The authors wish to add the following to the Competing Interests Section: "Dr. Wiendl has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Teva Pharmaceutical Industries Ltd.; has served/serves as a consultant for Merck Serono, Medac, Inc., Sanofi-Aventis/Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Novartis, and Novo Nordisk; and receives research support from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Sanofi-Aventis, Merck Serono, and Novo Nordisk."
Citation: Kroner A, Schwab N, Ip CW, Leder C, Nave K-A, Mäurer M, et al. (2011) Correction: PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation. PLoS ONE 6(1): 10.1371/annotation/51612e49-7bbe-4a84-b88d-fc5b7d79d853. doi:10.1371/annotation/51612e49-7bbe-4a84-b88d-fc5b7d79d853
Published: January 11, 2011
Copyright: © 2011 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.